Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/29/24
End: 10/31/26
Due: 10/31/27
Phase: N/A
Priority: Normal
Start: 06/21/21
End: 06/12/23
Due: 06/12/24
Phase: N/A
Priority: Normal
Start: 06/25/24
End: 09/17/24
Due: 09/17/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD) | NCT06335173 | Acumen Pharmaceuticals | user2@example.com | None | 2024-02-29 | 2026-10-31 | 2027-10-31 | - | - | 2025-07-14 |
| A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD | NCT04931459 | Acumen Pharmaceuticals | user2@example.com | None | 2021-06-21 | 2023-06-12 | 2024-06-12 | - | - | 2025-07-14 |
| A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants | NCT06511570 | Acumen Pharmaceuticals | user2@example.com | None | 2024-06-25 | 2024-09-17 | 2025-09-17 | - | - | 2025-07-14 |